27th Oct 2015 07:49
LONDON (Alliance News) - Circassia Pharmaceuticals PLC on Tuesday said sales of its NIOX asthma management products rose in the third quarter and in the first nine months of 2015, which it expects to continue in the remainder of the year, as it also readies the launch of its other allergy products.
The pharmaceutical company said sales of NIOX in the third quarter grew 35% to GBP4.5 million on the same period the year before, growing 30% to GBP13.6 million in the first nine months of the year.
"Circassia has made strong progress during the first nine months of 2015, and is well positioned to continue advancing each part of its newly-enlarged business. The company anticipates strong sales of its NIOX products during the rest of 2015, and the current expansion of its commercial capabilities should drive further growth in 2016," the company said in a statement.
"The coming months will be an important period of transformation as the company prepares for the launch of its first allergy product, while also boosting sales of the NIOX franchise. With results of Circassia's cat allergy phase III study and filings of its Seretide and Serevent substitute products expected by the end of the first half of 2016, the outlook is extremely exciting as the company accelerates towards its goal of becoming a self-sustaining specialty biopharmaceutical business," Circassia added.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CIR.L